Publicaciones en colaboración con investigadores/as de Guy's Hospital (126)

2023

  1. A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)

    The European respiratory journal, Vol. 61, Núm. 2

  2. A second update on mapping the human genetic architecture of COVID-19

    Nature

  3. Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 42-53

  4. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

    Blood Advances, Vol. 7, Núm. 9, pp. 1672-1681

  5. Early Time Courses of Recurrent Venous Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer

    Thrombosis and Haemostasis

  6. Impact of Post-PCI FFR Stratified by Coronary Artery

    JACC: Cardiovascular Interventions, Vol. 16, Núm. 19, pp. 2396-2408

  7. Lessons from COVID-19 in the management of acute respiratory failure

    Breathe, Vol. 19, Núm. 1

  8. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    European Urology

  9. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    European Journal of Cancer

  10. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

    The Lancet, Vol. 401, Núm. 10373, pp. 269-280

  11. Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial

    European Journal of Cancer, Vol. 184, pp. 48-59

  12. Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism

    European Journal of Internal Medicine, Vol. 112, pp. 29-36

  13. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study

    European Urology, Vol. 84, Núm. 3, pp. 321-330

2022

  1. A Novel Bead-Capture Nanopore Sequencing Method for Large Structural Rearrangement Detection in Cancer

    Journal of Molecular Diagnostics, Vol. 24, Núm. 12, pp. 1264-1278

  2. A Systematic Review of the Current Evidence from Randomised Controlled Trials on the Impact of Medication Optimisation or Pharmacological Interventions on Quantitative Measures of Cognitive Function in Geriatric Patients

    Drugs and Aging, Vol. 39, Núm. 11, pp. 863-874

  3. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

    Journal of the National Cancer Institute, Vol. 114, Núm. 1, pp. 109-122

  4. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

    Communications biology, Vol. 5, Núm. 1, pp. 1061

  5. International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis

    JAMA Dermatology, Vol. 158, Núm. 5, pp. 561-572

  6. Long-term topical management of psoriasis: the road ahead

    Journal of Dermatological Treatment, Vol. 33, Núm. 1, pp. 111-120

  7. Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 3, pp. 991-1003